Close Menu

NEW YORK — Bard1 Life Sciences has signed an agreement to acquire Sienna Cancer Diagnostics in an all-stock transaction, the Australian companies said on Wednesday.

Under the terms of the deal, Bard1 will issue 13 of its shares to Sienna shareholders for every five Sienna shares held. According to the companies, the deal values Sienna at roughly A$23.7 million ($14.8 million), or A$.06 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.